retatrutide phase 3 triumph Eli Lilly retatrutide Phase 3 obesity trial results 2026

Phase III retatrutide study demonstrates 30% weight loss

27.76

★★★★☆4.8 (126)

Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the

28.70

★★★★★4.9 (98)

🚨The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today 🚨

25.85

★★★★★5.0 (157)

First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, GLP-1 & Glucagon triple hormone receptor agonist drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the

28.19

★★★★★4.7 (84)

Retatrutide Phase 3 TRIUMPH: The Glucagon Receptor Nobody's Talking About

23.11

★★★★★4.9 (203)

🚨 Retatrutide TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35

25.93

★★★★★5.0 (176)

Retatrutide Phase 3: 60% Achieved Surgical-Level Weight Loss

21.76

★★★★★4.8 (132)